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ABSTRACT
Objective: The aim of the work was to determine the validation characteristics for the designed procedure for quantitation of the (S)-2,6-
diaminohexanoic acid substance, 3-methyl-1,2,4-triazolyl-5-thioacetate, by absorption spectrophotometry in the ultraviolet region.
Methods: For study purposes, the substance (S)-2,6-diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-5-thioacetate and a standard sample (SS) 
obtained from the State Enterprise “Chemical Reagents Plant” of the Scientific-Technological Complex “Institute of Single Crystals” of the National 
Academy of Sciences of Ukraine, was used. In the course of our work, we used chemical, physical, physicochemical (absorption spectrophotometry 
in the ultraviolet region), and statistical methods of analysis. The study was carried out at the Laboratory for Standardization and Technology of 
Medicines at the Department of Pharmaceutical Chemistry at the Zaporizhia State Medical University (Ukraine).
Results: In previous studies, we have developed a technique for spectrophotometric determination of the quantitative composition of (S)-2,6-
diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-5-thioacetate. The results of the conducted studies showed that the absorption curve in the UV region 
of the substance solution has a maximum absorption, namely: λ = 238 nm. The results of the quantitation of the substance (S)-2,6-diaminohexanoic 
acid of 3-methyl-1,2,4-triazolyl-5-thioacetate prove that our technique is accurate and reproducible and meets the current requirements. In order 
for the developed methodology to ensure consistent and accurate analysis results, its validation was carried out. According to the requirements of 
the State Pharmacopoeia of Ukraine (DFU) (2 editions), the developed method for the quantitation of the substance was checked for such validation 
characteristics as specificity, linearity, range of use, accuracy, correctness, and robustness.
Conclusion: As a result of the work, it was proved that the developed method of the quantitation of the substance (S)-2,6-diaminohexanoic acid of 
3-methyl-1,2,4-triazolyl-5-thioacetate by spectrophotometric method is valid.
Keywords: Ischemic heart disease, Spectrophotometry, Quantitation, Validation, (S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate.
INTRODUCTION
Cardiovascular diseases are fairly called the epidemic of the 20th century. 
For years, they are the leading cause of mortality in many developed 
countries, including Ukraine accounting for 55% of total mortality.
In the pathogenesis of acute focal cerebral ischemia, the primary 
importance belongs to the reduction of cerebral blood flow and 
development of circulatory hypoxia due to insufficient income 
of oxygen and glucose in the nervous tissue. The most promising 
methods of preventing irreversible damage to the brain substance 
in patients with ischemic stroke are to restore local cerebral blood 
flow (thrombolytic therapy) and metabolic brain protection and 
neuroprotection.
An important element in solving this complex problem is to create new 
highly effective and safe drugs, the use of which would lead to lower 
mortality and improve the quality of life.
Numerous experimental data and results of clinical usage of 
thiotriazoline and its combined dosage forms allowed revealing 
structural fragments of molecules that determine the presence 
and strength of anti-ischemic, antioxidant, neuroprotective, and 
cardioprotective activity. Analysis of the relationship “structure-
activity” allowed to determine the perspective direction of creating new 
biologically active compounds based on 1,2,4-triazole [1].
The staff of the Department of Pharmaceutical Chemistry of the 
Zaporizhia State Medical University, in cooperation with the specialists 
of the Scientific-Production Association “Pharmatron,” under the 
leadership of Professor Mazur I.A. during the chemical modification 
of the drug molecule - the leader of the thiotriazoline, new cationic 
anionic active compounds were obtained. The most active ingredient 
is a compound that combines the structural fragments of thiotriazolin 
and the amino acid of lysine in its molecule, called “Angiolin” - (S)-2,6-
diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate. (S)-2,6-
diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate shows 
cardioprotective, anti-ischemic, antioxidant, and neuroprotective 
properties with pronounced effects on the endothelium of the vessels 
of the brain and heart.
In our previous studies, a technique for spectrophotometric 
determination of the quantitative composition of (S)-2,6-
diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-5-thioacetate was 
developed. Therefore, the aim of our work was to determine the 
validation characteristics for the developed method of quantitation of 
the substance (S)-2,6-diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-
5-thioacetate by absorption spectrophotometry in the ultraviolet region.
METHODS
For study purposes, the substance (S)-2,6-diaminohexanoic acid of 
3-methyl-1,2,4-triazolyl-5-thioacetate and a standard sample (SZ) 
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obtained from the State Enterprise “Chemical Reagents Plant” of the 
Scientific-Technological Complex “Institute of Single Crystals” of the 
National Academy of Sciences of Ukraine was used. In the course of our 
work, we used chemical, physical, and physical-chemical (absorption 
spectrophotometry in the ultraviolet region and absorption 
spectrophotometry in the infrared region) analysis methods. The study 
was carried out at the Laboratory for Standardization and Technology 
of Medicines at the Department of Pharmaceutical Chemistry of the 
ZSMU.
RESULTS AND DISCUSSION
In previous studies, we have developed a technique for 
spectrophotometric determination of the quantitative composition of 
(S)-2,6-diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-5-thioacetate. 
The results of the studies showed that the absorption curve in the UV 
region of the substance solution has the absorption maxima, namely: 
λ=238 nm. The results of the quantitative determination of the 
substance (S)-2,6-diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-
5-thioacetate spectrophotometrically prove that our technique is 
accurate and reproducible and meets the current requirements [2,3].
For a high degree of assurance that the substance meets the pre-
established eligibility criteria; in particular, validation of technological 
processes is carried out using samples of at least three series of real 
product to confirm and provide a documentary evidence that the 
process (within the established parameters) has a repeatability and 
leads to the expected results in the production of semi-finished product 
or finished product of the required quality; validation of analytical 
methods is to determine accuracy, reproducibility, sensitivity, stability, 
linearity, and other metrological characteristics.
Testing the stability of the reference solution is one of the elements 
of studying the robustness of the technique and should be carried out 
before the start of all other validation studies. As a result of our study, 
it has been proved that our solution is stable for at least an hour. For 
this, a parallel measurement of the optical density of the solution was 
performed at different times t=0, 15, 30, 45, and 60 min. The results 
of testing the stability of our solution at different times are shown in 
Table 1.
The linear dependence was studied within the range of use of the 
developed techniques. It was confirmed directly on tablets by dilution 
of standard solutions (nine concentrations were used). Based on the 
obtained data, the graphs of the dependence of the optical density of the 
solutions obtained from their concentration were made. The obtained 
results were processed using the least squares method, and the linear 
regression equations of general form were calculated: y=a+b·x, where 
y - is the measured value (optical density), x - is the concentration of the 
determined medicinal substance, a - is a free line of linear dependence 
for the calculated regression line, and b - is the angular coefficient for 
the calculated regression line. To quantify the reproducibility of the 
results of the definitions and the adequacy of the linear dependence, 
the numerical values of the linear dependence were calculated, namely, 
the correlation coefficient R (should be greater than the general 
correlation index Rc), the residual standard deviation S0 (should not 
exceed the maximum uncertainty of the analysis ΔAs), the free member 
of the linear regression a (|a| ≤Δа) and regression b coefficient, and 
linear dependence are shown in Table 2.
The calculated numerical values of linear dependence indicate that 
the linearity meets the requirements of the DFU in the selected 
concentration ranges (Fig. 1).
According to the requirements of the DFU, such validation 
characteristics as the correctness and accuracy of the developed 
methods for quantitation of the active substance in the drugs 
composition were established by the method of model mixtures 
(Table 3). The general objective in determining the correctness of 
the techniques is to identify possible systematic errors that arise as 
a result of influencing the results of definitions of excipients that are 
part of the drug [4,5].
Precision (intra-laboratory precision) of the technique is determined 
by the proximity of the results for a series of measurements 
carried out according to this method in different samples of the 
same homogeneous sample and is conditioned by the presence of 
random errors. According to the DFU, the precision of the technique 
is considered at three levels as follows: Intralaboratory precision, 
convergence, and reproducibility [6-8]. In this study, the precision of 
the proposed method was determined on the level of convergence. To 
do this, in each case, 15 parallel determinations were carried out (five 
weighs and three repetitions), and metrological characteristics were 
determined according to the results. According to the data shown 
in Table 4, it is established that in all cases the one-way confidence 
interval does not exceed the maximum permissible uncertainty 
of the analysis; therefore, the methods are accurate at the level of 
convergence.
The range of use of the analytical technique is the interval between the 
minimum and maximum concentrations of the test substance, for which 
it is shown that the technique has the required linearity, correctness, 
and precision. According to the results of the carried out study, usable 
ranges for the developed techniques are within the working intervals 
for the methods of quantitation according to the DFU requirements 
(80–120%) [9,10].
The assessment of workability was carried out at the stage of 
development of techniques by identifying factors that influence the 
Table 1: Stability of the solution of (S)‑2,6‑diaminohexanoic acid of 3‑methyl‑1,2,4‑triazolyl‑5‑thioacetate
t, min 0 15 30 45 60 Mean RSDt% ∆t% max
A0 0.485 0.485 0.486 0.486 0.486 0.486 0.11 0.23 0.56
A 0.481 0.481 0.482 0.482 0.483 0.482 0.17 0.30 0.56
RSD: Relative Standard deviation
Table 2: Metrological characteristics of linear dependence y=a + bx
Value name Data value Criteria (for 98.5‑101.0% allowance, number of points 9) Result (match or does not match)
b 1.0206 − −
Sb 0.0109 − −
a 1.9315 ≤1.8946* Sa=0.14;
If it does not realize 1),
then≤2.5
correspond
Sa 0.0776 − −
Sr 0.9992 ≤1.24 −
R 0.9996 ≥0.99535 correspond
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magnitude of optical density. The influence of these factors was taken 
into account when choosing the best conditions for determination.
As a result of the work, it was proved that the method of quantifying the 
determination of the (S) -2,6-diaminohexanoic acid of 3-methyl-1,2,4-
triazolyl-5-thioacetate according to characteristics such as specificity, 
linearity, correctness, range of use, precision, and robustness are valid.
The developed method of quantitative determination of substance by 
absorption spectrophotometry method in the ultraviolet region will be 
further used to develop methods for the analysis of tablet formulations 
of (S) -2,6-diaminohexanoic acid of 3-methyl-1,2,4-triazolyl-5-
thioacetate.
CONCLUSION
In the course of the work analyzed the data of scientific literature on 
the prevalence of the incidence of the Ukrainian population of CHD, the 
prospects for the creation of new metabolito tropic cardioprotective 
drugs. The procedure of validation of the method of quantitative 
determination of angiolin in substance by spectrophotometric method 
is carried out. A forecast of the maximum permissible uncertainty of the 
analysis is conducted, the results of which satisfy the requirements of 
the (SPF) State Pharmacopoeia of Ukraine. Validation characteristics are 
investigated for the method: stability, robustness, linearity, correctness, 
convergence, and reproducibility. The results prove that the technique 
can be properly restored and suitable for future use.
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